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Background and purpose: To compare early (3 and 6 month) and later (12 and 24 month) functional outcomes of
stage III and IV (M0) oropharyngeal squamous cancer patients treated in sequential cohorts with 3D conformal
(3DCRT) or intensity modulated radiotherapy (IMRT).
Patients and methods: 200 patients in sequential population based cohorts of 83 and 117 patients treated at a
single institution with 3DCRT and then IMRT respectively were prospectively assessed at pre-treatment and 3, 6, 12
and 24 months post treatment. A standard functional outcomes protocol including performance status (KPS,
ECOG), 3 Performance Status scales for Head and Neck (PSS-HN), the Royal Brisbane Hospital Outcome Measure
for Swallowing (RBHOMS), Voice Handicap Index-10 (VHI-10) and self-rated xerostomia were applied.
Results: Mean age at diagnosis was 59 years. The primary site was base of tongue in 77 and tonsil or soft palate
in 123 patients. Median follow up was 2.5 years for the second cohort. Concomitant therapy was used in 159
(79.5%). Overall survival at 3 years was 75.6% and 71.5% for IMRT and 3DCRT cohorts respectively (not significant).
A multiple imputation technique was used to estimate missing values in order to avoid a healthy patient bias.
KPS and ECOG reached nadirs at 3 to 6 months but approached baseline values at 12 to 24 months and did not
differ by treatment. The 3 PSS-HN scales, Eating in Public (p < 0.001), Understandability of Speech (p = 0.009) and
Oral Diet Texture (p = 0.002) and all showed significantly better outcomes in favor of IMRT. The RBHOMS showed a
difference in favor of IMRT which appeared during 3 to 6 months (p < 0.001). The VHI-10 also showed a difference in
favor of IMRT (p = 0.015). Self-rated xerostomia did not differ at 3 and 6 months but was significantly better in favor of
IMRT after 12 months p = 0.005
Conclusions: A prospectively administered functional outcomes protocol showed meaningful differences in favor of
IMRT over 3DCRT early (3–6 months) and later (12–24 months) in the treatment of oropharyngeal carcinoma with
equivalent survival. These data support the adoption of IMRT as the standard radiation treatment method for patients
with stage III and IV (M0) oropharyngeal squamous carcinoma. KPS and ECOG may not be sensitive to oropharyngeal
cancer patients’ functional outcomes by treatment.
Keywords: Oropharyngeal, Intensity modulated, Functional outcomes* Correspondence: acooke1@cancercare.mb.ca
2Cancer Care Manitoba, Winnipeg, Manitoba, Canada
4Department of Radiation Oncology, CancerCare Manitoba, 675 McDermot
Avenue, Winnipeg, Manitoba R3E 0 V9, Canada
Full list of author information is available at the end of the article
© 2015 Kerr et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Kerr et al. Journal of Otolaryngology - Head and Neck Surgery  (2015) 44:17 Page 2 of 8Background
Organ preservation protocols using chemo-radiotherapy
for stage III and IV (M0) oropharyngeal squamous
carcinoma have been developed to preserve anatomy
and function. However acute and long term toxicities
remain problems with the organ preservation approach.
Long term toxicities related to radiation include chronic
ulceration, xerostomia, pharyngeal constrictor dysfunc-
tion, esophageal stricture, impaired swallowing, PEG
tube dependency, laryngeal edema and neck fibrosis
[1,2]. However these specific narrow indicators of treat-
ment related dysfunction may not necessarily correlate
with broader quality of life and performance status
which may be more meaningful for patients.
Intensity modulated radiation therapy [IMRT] offers an
opportunity to generate dose distributions more con-
formal to the target volumes including tumor, involved
nodes and areas at risk compared to its predecessor, 3D
conformal radiotherapy (3DCRT) with relative sparing of
surrounding normal tissues [3]. Reduction of the mean
dose to the parotid gland by IMRT is feasible and corre-
lates with a reduction in patient and observer-rated xeros-
tomia [4]. Relative sparing of the pharyngeal, laryngeal
and cervical esophageal swallowing structures outside the
PTV is also possible with IMRT to avoid grade 3–4 late
dysphagia and cervical esophageal stricture [5].
Two completed randomized phase III trials have com-
pared the toxicity of IMRT with 3DCRT [6-8] in oropha-
ryngeal cancer patients. The GORTEC 2004–01 is in
progress [www.gortec.fr]. The trials are small, or had a het-
erogeneous population (i.e. included hypopharynx or larynx
patients) or had endpoints that are limited to xerostomia
and salivary function. One trial [8] used the EORTC QOL
QLC-C30 with the Head and Neck Module (HN35) to as-
sess 58 patients at least once. They concluded that IMRT
when compared to 3DCRT resulted in clinically meaningful
and statistically better QOL scores.
There are several non-randomized comparisons of IMRT
vs. 2DRT or 3DCRT in head and neck patients (excluding
NPC) [4,9-13] using a variety of instruments, heteroge-
neous populations and different time points for measure-
ment which demonstrate patients treated with IMRT
experience statistically meaningful improvements in several
important QOL domains. IMRT has nevertheless been
widely implemented with this limited information.
To address these issues we have prospectively collected
standardized longitudinal clinical performance status and
functional outcomes on 2 sequential population based co-
horts of patients with stage III and IV(M0) oropharyngeal
carcinoma treated at one institution.
Methods
The methodology has been described in a previous
publication regarding oropharyngeal cancer patientstreated with 3DCRT at this institution to 2008 [14]. All
patients diagnosed with carcinomas of the head and
neck and considered for curative intent between 2003
and 2011 were reviewed in a multi-disciplinary consen-
sus conference to confirm site, histology and TNM
stage and to determine treatment intent and modal-
ity(s). Patients were included in this study if they had
American Joint Committee on Cancer (AJCC) stage III
or IV (M0) squamous cell carcinoma of the oropharynx
and were treated with 3DCRT or IMRT (after 2007),
either with or without concomitant cisplatin or cetuxi-
mab and with curative intent (typically 66–70 Gy in
2 Gy fractions to gross disease). Neck irradiation was
bilateral except in highly selected patients with cancers
of the tonsil with N1 disease. Over the period of the
two cohorts the selection and treatment polices for oro-
pharyngeal stage III and IV cancers did not change
except for the implementation of IMRT and the addition
of cetuximab in some cases not eligible for cisplatin.
Neck dissection for bulky neck nodes prior to or after
radiation was allowed. Patients were excluded if they
were treated with surgery alone, surgery to the primary
tumor (with or without post-operative radiotherapy), or
had a previous head and neck cancer within five years
prior to diagnosis. Human papilloma virus [HPV] infec-
tion was not assessed in the early years of the study and
is not included in the analysis.
The Manitoba Cancer Registry [MCR] is a compre-
hensive and accredited population-based registry for
1.2 million people. The MCR is a member of the North
American Association of Central Cancer Registries
which administers a program that reviews member
registries for their ability to produce complete, accurate,
and timely data. Fields include diagnosis coded using the
International Classification of Diseases 10th revision
for Canada (ICD-10-CA), age, and TNM stage. Medically
necessary care is freely provided to all Manitobans without
premiums or co-payments and non-participation in the
plan is rare [www.gov.mb.ca/health/guide/2.html]. There-
fore the registry and any derived cohort can be considered
complete and population-based. All incident registry cases
from 2003 to 2011 inclusive with oropharyngeal cancer
were reviewed to ensure all cases were included.
Patients were assessed prospectively by one Speech
Language specialist (CM) using a standardized clinical
functional outcomes protocol at a pre-treatment visit
and post-treatment at 3, 6, 12, 24 and 36 months. In the
first year, assessments could vary by as much as +/−
1 month. At 24 and 36 months visits could vary within
several months. Pre-treatment assessment was not a
protocol standard until March of 2005. The following
data were also collected: gender, age at diagnosis, weight
at each visit, date of placement and removal of feeding
tube if used, chemotherapeutic agents used, amifostine
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clinically, radiographically or pathologically, site of recurrence,
date of death, hospitalizations, tobacco use, and incidence
of respiratory infections.Functional outcomes protocol
The protocol was intended to capture functional out-
comes beyond recurrence and survival consistent with
the International Classification of Functioning, Disability
and Health (ICF) 22–23. The protocol included 8 instru-
ments which have proven inter-rater reliability and
validity and are widely used in head and neck cancer
patient assessments. The protocol was applied prospect-
ively, in face to face interviews with patients by a single
speech language pathologist (CM).
The Karnofsky Performance Status (KPS) scale [15]
and the Eastern Cooperative Oncology Group (ECOG)
toxicity and response criteria scale [16] are clinician-
rated standard tools used to assess performance in
activities of daily living.
The Performance Status Scale for Head and Neck
Cancer Patients (PSS-HN) [17] is a clinician rated inter-
view assessment tool that describes performance on
three subscales: Eating in Public, Understandability of
Speech and maximum Oral Diet Texture. Each PSS-HN
scale has a 5 or 10 point ordinal scale (nominally from 0
to 100) with higher scores indicating better performance.
The PSS-HN has good inter-rater reliability and ability
to discriminate levels of functioning [18]. For graphic
purposes but not for analysis the PSS-HN ordinal scales
are here represented as 4 ranges for Eating in Public
PSS-HN and Oral Diet Texture PSS-HN and 3 ranges
for Understandability of Speech PSS-HN.
The Royal Brisbane Hospital Outcome Measure for
Swallowing (RBHOMS) [19] is a clinician-rated 10-
point scale which measures oral intake, swallowing
function and relative dependence on enteral tube
feeding. For graphic purposes the scale was collapsed
into 4 ranges. The ranges were 1–3, (total tube
dependence, NPO), 4–5, (reduced oral intake requir-
ing partial or total tube feed supplementation), 6–7,
(modified diet with no tube supplementation), and >8,
(oral intake at optimum level).
The Voice Handicap Index-10 (VHI-10) [20] is a
patient-rated scale with 10 questions with answers
ranging from 0 (never) to 4 (always) for a total of 40
possible points with a higher score indicating worse
self-perceived voice handicap. The VHI-10 has been
collapsed into 3 ranges, 0–9 (never to almost never se-
vere), 10–19 (sometimes severe), and > 20 (more than
sometimes severe).
Finally self-rated xerostomia on a 0–10 scale from the
Edmonton Self-Assessment Scale (ESAS) [21] was collected.Statistical analysis
Overall survival (OS) and disease-free survival (DFS), for
which events are recurrence without death and death
from any cause, were measured from the time of
diagnosis and compared by the logrank test. Patients
with recurrence were followed and assessed until death
or end of study follow-up. Patients were censored at the
time of death, with or without recurrence.
Times for functional outcome assessments were mea-
sured from the date of the last radiation treatment.
Compliance with the functional outcome protocol was
measured as the percentage of patients administered a
questionnaire out of all patients alive at that time.
Missing assessments while patients were alive were
considered to be missing at random (MAR) if they were
the result of a conflict in schedule or because assess-
ments were not systematically scheduled for pretreat-
ment, 3 and 6 months at the beginning of data
collection. Missing values were estimated using a mul-
tiple imputation bootstrap method [22]. Because the
outcomes were skewed, the ICE procedure in Stata
11.2 (StataCorp LP, College Station Tx) [23] was used
for multiple imputations, which uses a conditional density
approach. Pre-treatment outcomes were imputed first,
using gender, stage, subsite, and age as predictors. Based
on Graham [24] 20 imputations were used.
Post-treatment outcomes were then merged to the
new pre-treatment dataset and imputed once, using
gender, stage, subsite, age, month of assessment, and
pre-treatment assessment as predictors. Results by treat-
ment were compared with mixed logistic or ordinal
models using GLLAMM in Stata. Adjustments to com-
parisons by treatment were made for variations in pre-
treatment function.
Xerostomia was analyzed by mixed quantile regression
using lqmm in R 2.15.2.
This study was approved by the University of Manitoba
Health Research Ethics Board.
Results
From 2003 to 2011, 200 patients with stages III and IV
(M0) squamous cell carcinoma of the oropharynx were
treated with curative intent using 3DCRT (83) or IMRT
(117) with or without concomitant therapy. Patient and
treatment characteristics are shown in Table 1. One
patient had a suspected tonsil primary but had only CIS
on biopsy but had grossly involved regional nodes and has
been included. Two significant differences were noted be-
tween the cohorts. Cetuximab was introduced for some
IMRT patients not eligible for cisplatin (typically older or
with renal impairment) and the lower number of 3 and
6 month assessments done in the 3DCRT group.
Median follow up is approximately 2.5 and 3.5 years
for IMRTand 3DCRT patients respectively. Overall survival
Table 1 Sequential cohort patient characteristics
IMRT 3DCRT
(N = 117) (N = 83) p
Age mean (SD) 59.9 (9.0) 58.8 (9.5) 0.41
Gender F (%) 18 (15.4) 19 (22.9) 0.20
M 99 (84.6) 64 (77.1)
T stage 1 or 0* (%) 28 (23.9) 14 (16.9) 0.52
2 42 (35.9) 30 (36.1)
3 28 (23.9) 20 (24.1)
4 19 (16.2) 19 (22.9)
N Stage 0 (%) 15 (12.8) 12 (14.5) 0.28
1 16 (13.6) 18 (21.7)
2 83 (70.9) 51 (61.4)
3 3 (2.6) 2 (2.4)
Stage III (%) 20 (17.1) 19 (22.9) 0.37
IV 97 (82.9) 64 (77.1)
Primary site Tongue Base (%) 41 (35.0) 36 (43.4) 0.24
Tonsil, soft palate 76 (65.0) 47 (56.6)
Concomitant Cisplatin (%) 85 (72.6) 62 (74.7) 0.01
Cetuximab 12 (10.3) 0 (0)
No 20 (17.1) 21 (25.3)
Assessments 3 months (%) 95.7 72 <0.0001
6 98.2 90.2 0.02
12 92.2 90.8 0.96
24 91.2 95.3 0.49
*1 patient had grossly involved tonsil but bx showed only CIS with
gross nodes.
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shown in Figures 1 and 2. There was no significant differ-
ence between IMRT and 3DCRT for either OS (76 vs. 71%
p = 0.71) or DFS (72 vs. 71% p = 0.88 ). Cause specific
mortality (not shown) at 3 years was also not significantly
different (17 vs 21%). Recurrence of any sort carried a poor
prognosis. Only 1 patient with a local recurrence and
1 patient with a regional recurrence had successful surgical
salvage and were alive without disease at the last follow up.
Functional outcomes
Functional outcomes are shown to 2 years of follow
up. KPS is shown in Figure 3A. There is a nadir at the
3 month assessment with recovery to approximately
pre-treatment values by 24 months but there is no
difference by treatment (p = 0.234). ECOG is shown in
Figure 3B. Similarly there is a nadir with recovery but
there is only a non-significant trend by treatment in
favor if IMRT (p = 0.078). On the other hand (data not
shown) both KPS and ECOG were significantly pre-
dictive of death from any cause within 1 year irre-
spective of treatment.All the following comparisons have been adjusted for
baseline differences and death. PSS-HN results are
shown in Figures 3C,D and E. Eating in Public PSS-HN
(Figure 3C) shows a significant difference in favor of
IMRT predicting no restriction vs. any restriction (100 vs.
75 and lower) OR 0.164 (95 %CI, 0.07-0.39 p = <0.001).
For Eating in Public PSS-HN, at 12 and 24 months
83% and 82% of IMRT survivors had no restrictions
compared to 49% and 64% of 3DCRT survivors
respectively. The Understandability of Speech PSS-HN
(Figure 3D) shows only <4% of patients with speech
that was difficult to understand pretreatment and in
the first 6 months. Thereafter no survivor was difficult
to understand. Nevertheless a significant benefit in
favor of IMRT (100 vs. 75 and lower) was noted, OR
0.294 (95% CI, 0.12-0.73 p = 0.009). Oral Diet Texture
PSS-HN (Figure 3E) shows marked deterioration in
both groups that did not recover to baseline even at
24 months with large subgroups preferring soft chew-
able food regardless of treatment. While little differ-
ence by treatment is seen at 3 and 6 months, there is a
difference in favor of IMRT appearing at 12 and
24 months with an overall significant difference in
favor of IMRT, OR 0.346 (95% CI, 0.18-0.67 p = 0.002).
At 12 and 24 months 22% and 25% in the IMRT group
had no Oral Diet Texture restrictions compared to 7%
and 5% for 3DCRT survivors respectively.
The RBHOMS (Figure 3F) shows that pretreatment,
fewer than 3% of patients in either group had partial or
complete tube dependency. At 3 months, 46% in the
3DCRT group and 21 % in the IMRT group were par-
tially or completely tube dependent. By 24 months par-
tial tube dependency had declined to 3% in the 3DCRT
group and 5% in the IMRT group and no survivor was
totally tube dependent. Overall there was a significant
benefit in favor of IMRT (8 vs. 7 or lower) OR 0.138
(95% CI, 0.06-0.33 p < 0.001).
The VHI-10 (Figure 3G) shows a significant benefit in
favor of IMRT (0, 1–9 and 10+) OR 0.492 (95% CI,
0.28-0.87 p = 0.015) but function did not return to pre-
treatment levels.
Self-reported xerostomia (Figure 3H) shows little no
difference by treatment at the 3 and 6 month assess-
ments but there is a significant time-treatment inter-
action with improvements in favor of IMRT appearing
at 12 months onward with a difference in median score
of −1.232 (95% CI, −2.09—0.37 p = 0.005)
Discussion
The widespread implementation of IMRT in place of
3DCRT for head and neck cancer has been justified by
surrogate end points such as dose volume histograms
and uncontrolled series with various endpoints. Limited
randomized controlled information comparing 3DCRT
Figure 1 Overall survival.
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pertains to oropharyngeal carcinoma. Because narrow
measures of salivary function or swallowing may not
necessarily reflect patients’ perceptions or overall func-
tional outcome acutely or longer term, we have applied
a functional outcomes protocol in order to more
broadly assess outcomes. The population-based nature
of our data implies that case selection beyond the
actual indications for treatment has not occurred and
that these results may be reliable and generalizable.
Further, the prospective interview and self-rating based
data are additional features that suggest our data are
reliable indicators of patient function at various times
after treatment.Figure 2 Disease free survival.One weakness of the study is that compliance was not
100% for all assessments and lower at 3 and 6 months
for 3DCRT (Table 1). We have attempted to address this
possible shortcoming by a multiple imputation tech-
nique that takes into account individual patient’s scores
to estimate missing values. At 12 and 24 months, where
long term toxicities become important, assessment
compliance was equivalent. Another weakness of the
study is that for graphic purposes (but not for the
statistical model analysis) we have censored patients
who have died between assessments. Because death also
censors functional assessments, some of the functional
“improvement” seen over the months of follow up is





Figure 3 Functional outcomes in sequential population based cohorts by treatment. A. Performance status (KPS) over time by treatment. B. Performance
status (ECOG) over time by treatment. C. Eating in public (PSS-HN) over time by treatment. D. Understandability of Speech (PSS-HN) over time
by treatment. E. Oral diet texture (PSS-HN) over time by treatment. F. Swallowing (RBHOMS) over time by treatment. G. Voice handicap (VHI-10) over
time by treatment. H. Xerostomia (ESAS) over time by treatment.
Kerr et al. Journal of Otolaryngology - Head and Neck Surgery  (2015) 44:17 Page 6 of 8in survivors, but will instead be due to the deaths of
those who are likely to have poor function. Thus the
changes in functions graphically represented over time
after treatment cannot be looked at as simply recovery
of the cohort, but only a statement of the function ofthe survivors at certain specific times after treatment.
Also, the two cohorts differed somewhat in their base-
line pre-treatment scores. As much as possible, we have
adjusted the comparisons for the differences in the pre-
treatment scores and the OR and p values we report
Kerr et al. Journal of Otolaryngology - Head and Neck Surgery  (2015) 44:17 Page 7 of 8are adjusted. We did not report on HPV because in the
early years of the study this was not routinely measured.
The similar demographics and survival of the two cohorts
(Table 1, Figures 1 and 2) suggest that HPV status which
can profoundly affect outcome [25] did not differ greatly
between the two groups. Finally cetuximab was intro-
duced during the IMRT cohort, primarily for those who
would not be able to take cisplatin, such that percentage
receiving cisplatin remained much the same in both co-
horts, 74.7 vs 72.6%. If cetuximab added toxicity this
would bias the results against IMRT.
We have documented both early post-treatment func-
tional impairments (3 and 6 months) and those that
occur later (12 and 24 months). The RBHOMS shows
significant differences that appear soon after treatment
at 3 to 6 months and the Eating in Public PSS-HN, Oral
Diet Texture PSS-HN and self-rated xerostomia scale
show differences that mostly appear at 12 to 24 months.
IMRT in our study is therefore broadly superior to
3DCRT by different measures at different times and pro-
vides a persistent meaningful benefit to patients.
The effect of treatment on these functional outcomes
is likely due to the effect of (chemo) radiation on mul-
tiple end points in composite including oropharyngeal
mucous membranes, pharyngeal constrictors, taste and
salivary gland function [7,26] but we cannot ascertain
the degree to which any of these or any other compo-
nent of eating contributes to these functional endpoints.
Presumably the additional conformality afforded by
IMRT in comparison to 3DCRT is responsible for the
differences seen in our study.
Conclusions
In sequential population-based cohorts of 200 stages III
and IV (M0) oropharyngeal cancer patients treated with
3DCRT and IMRT, with or without concomitant therapy
OS and DFS did not significantly differ by treatment.
While both treatments resulted in functional impairment
at 3–6 months after treatment, significant differences
were seen at 3 and 6 months in favor of IMRT as
measured by RBHOMS, and later at 12 and 24 months
as measured by the PSS-HN scales for Eating in Public,
Oral Diet Texture, Understandability of Speech, the Voice
Handicap Index (VHI) and xerostomia as assessed by the
Edmonton Self-Assessment Score (ESAS). KPS and ECOG
however did not show any differences by treatment.
However, KPS and ECOG may not be sensitive to oropha-
ryngeal cancer patients’ functional outcomes by treatment.
IMRT maintained efficacy of treatment with improved
functional outcomes indicating an improved therapeutic
ratio compared to 3DCRT in patients with oropharyn-
geal squamous carcinoma stage III and IV(M0). These
data support IMRT as the standard of care for curative
(chemo) radiation for such patients.It is unlikely given the established place IMRT has
in the treatment of head and neck cancer that much
additional data will be available from randomized
controlled trials of IMRT vs. 3DCRT apart from the
pending GORTEC 2004–01 trial.
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